Biodistribution and toxicity evaluation of sesbania mosaic virus nanoparticles in mice

Abstract

Sesbania mosaic virus (SeMV), a 30-nm spherical plant sobemovirus, is suitable for developing functionalized nanoparticles for biomedical applications. However, the in vivo behavior of SeMV and the clinical impact following its delivery via the oral or intravenous route are not known. To address this question, we examined the biodistribution, toxicity and histopathological changes in SeMV treated mice. No toxic effects were observed in mice administered high doses (100 mg and 200 mg per kg body weight orally or 40 mg and 80 mg per kg body weight intravenously) of SeMV, and they were found to be normal. Analysis of fecal sample showed that SeMV was cleared in 16 h when 20 mg of the virus per kg body weight was administered orally. RT-PCR analysis of blood samples showed that SeMV was present up to 72 h in mice inoculated either intravenously (8 mg/kg body weight) or orally (20 mg/kg body weight). Further, SeMV was found to be localized up to 72 h in spleen and liver tissues of intravenously inoculated mice only. Biochemical and hematological parameters were found to be normal at 6 and 72 h after administration of SeMV. Furthermore, no noticeable changes were observed in histological sections of brain, liver, spleen, lungs and kidney tissue samples collected at 6 and 72 h from SeMV administered mice when compared to control mice. Thus, SeMV appears to be a safe and non-toxic platform that can be tailored as a nanocarrier for in vivo biomedical applications.

Engineering hepatitis B virus core particles for targeting HER2 receptors in vitro and in vivo

“…The clearance kinetics of proteins and VLPs have been reported in several studies [3] , [57] , [58] , [59] . In general, particulate materials including viral proteins are removed from the blood circulation relatively quickly by the reticulo-endothelial system (RES) (e.g.…”

Oral Delivery of Nanoparticles Carrying Ancestral Uricase Enzyme Protects against Hyperuricemia in Knockout Mice

“…We have demonstrated that a recombinant ancestral uricase packaged in Qβ nanoparticles and orally delivered to uricase-knockout mice is able to prevent the buildup of endogenous uric acid levels and suppress some of the renal damage caused by hyperuricemia during a limited treatment regime. The use of virus-like particles as oral vaccine candidates is well known, and a few accounts have described or inferred remarkable stability of different VLPs toward the degradation in the GI tract − While we have not directly analyzed the fate of Qβ VLPs after oral delivery, the retention of significant uricase activity, presumably in the intestine, suggests that this particle also resists digestive enzymes and acidic hydrolysis, and imparts hydrolytic stability to the packaged enzyme as well.…”

Plant Viruses as Adjuvants for Next-Generation Vaccines and Immunotherapy

“…Large quantities of these viruses readily accumulate in plants, and the extraction and purification of plant viruses is efficient (and economically feasible in terms of time and materials). Moreover, many plant viruses are stable, particularly under physiological conditions, so that strict adherence to the vaccine chain is not required for storage and transfer [ 1 , 2 , 3 , 4 , 5 , 6 , 7 ].…”